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Abstract
Background: Artemisinin-containing therapies are highly effective against Plasmodium falciparum
malaria. Insufficient numbers of tablets and inadequate package inserts result in sub-optimal dosing
and possible treatment failure. This study reports the case of three, non-immune, expatriate
workers with P. falciparum acquired in Africa, who failed to respond to artemisinin-based therapy.
Sub-therapeutic dosing in accordance with the manufacturers' recommendations was the probable
cause.
Method:  Manufacturers information and drug content included in twenty-five artemisinin-
containing specialities were reviewed.
Results: A substantial number of manufacturers do not follow current WHO recommendations
regarding treatment duration and doses.
Conclusion: This study shows that drug packaging and their inserts should be improved.
Background
Artemisinin derivatives, such as artesunate, artemether
and dihydroartemisinin, are the most parasiticidal of all
the antimalarial drugs against Plasmodium falciparum [1].
Their pharmacokinetic (rapid absorption, short half life
~1 hour) and pharmacodynamic (high parasite reduction
ratio) properties mitigate against the development of
resistance. In vivo resistance to this drug class has not yet
been described [2]. However, several challenges remain,
including the limited availability of GMP quality drugs,
the emergence of fake drugs, and their optimal deploy-
ment in malaria-endemic countries. Artemisinin-based
drugs are easily available in several malaria-endemic
countries and are sold as mono- or combination thera-
pies. They are manufactured in several countries, pack-
aged differently and contain package inserts of varying
quality and accuracy. WHO currently recommends
malaria-endemic countries to use three days of an artem-
isinin-based combination treatment (ACT) e.g. arte-
mether/lumefantrine (A/L), artesunate (4 mg/kg/day)
plus an effective, longer acting partner drug, such as amo-
diaquine or mefloquine [3]. If used alone, seven days of
treatment of an artemisinin derivative is necessary
because shorter courses result in unacceptably high rates
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of recrudescence. Most recently, WHO has called drug
manufacturers to switch the production of artemisinin
monotherapies towards combined therapies because of
the risk of developing drug resistance. Artesunate mono-
therapy of ≤ 5 days duration in South-East Asian and Afri-
can patients is associated with a failure rate of up to 50%
and the four doses regimen of artemether/lumefantrine
has resulted in failure rates of between 15 to 18% in Afri-
can children, Thai adults and non immune travellers [4-
11]. Recrudescent falciparum malaria is associated with a
risk of developing severe malaria, especially in non-
immune individuals, such as travellers or expatriate work-
ers.
Probable recrudescent P. falciparum malaria was recently
diagnosed in three non-immune Europeans at the Geneva
University Hospital. These three patients were initially
treated in sub-Saharan Africa with artemisinin-based
drugs. This motivated a thorough examination of package
inserts of artemisinin-based drugs available in Africa. The
potential association between treatment failure and inad-
equate information on drug leaflets are discussed in this
study.
Case report 1
Patient 1 was a 27 year old Swiss female working in Sudan
for an international NGO. She was not taking antimalarial
chemoprophylaxis. She developed a febrile illness that
was diagnosed locally as malaria by positive microscopic
examination (species and parasitaemia unknown) and
Paracheck™, a rapid diagnostic test that detects P. falci-
parum-specific histidine-rich II protein. By inference, she
was infected with P.falciparum either alone or mixed with
another Plasmodium species. She self-prescribed oral arte-
mether, obtaining the drug from the NGOs pharmacy.
She did not recall the dose of artemether, but she reported
full compliance with the five days course contained in the
package. She improved on this treatment, but four days
after stopping artemether, she developed fever again and
had a positive malaria blood smear (species and parasitae-
mia unknown) consistent with a recrudescence of her pri-
mary infection. She was retreated with the same five days
regimen with good effect. Some three and a half weeks
later, she suffered a recurrence of fever associated with a
positive malaria smear (species and parasitaemia
unknown) suggesting either a recrudescence of her initial
infection or a new infection. PCR genotyping was unavail-
able to differentiate her recurrent illness. She received
artemether for seven days in combination with a single
dose (three tablets) of sulfadoxine/pyrimethamine and
had no further episodes of malaria while in Sudan. On
review at the Geneva Hospital six weeks after her last
febrile episode, she was well and afebrile.
Case report 2
Patient 2 was a 35 years old Swiss woman working in rural
Côte d'Ivoire for another international NGO. She was not
on malaria prophylaxis. She developed fever and was
found with a positive blood slide for malaria. Although
the species was not specified, P. falciparum was the likely
diagnosis given the high prevalence of P.  falciparum
locally. However, a mixed infection cannot be formerly
ruled out. She was treated at a local clinic with a single
dose of intramuscular quinine in combination with the
four doses regimen (four tablets × 4 over 48 hours) of arte-
mether/lumefantrine (A/L); the latter is marketed as
CoArtem® in malaria endemic countries. She made an
uneventful recovery and then started daily chloroquine/
proguanil (Savarine®) as prophylaxis. Twelve days after
completing her A/L, she presented at Geneva Hospital
with fever and had a positive malaria slide, with a P.falci-
parum asexual parasitaemia of 4,000/μL. She was treated
successfully with three days of atovaquone/proguanil,
remaining afebrile and aparasitaemic during 28 days of
follow up.
Case report 3
Patient 3 was a 30 years old Swiss man who was working
in Guinea Conakry. He took weekly mefloquine as proph-
ylaxis and reported good compliance. However, he devel-
oped an acute febrile illness that was diagnosed as malaria
by blood smear. He was unaware of the Plasmodium spe-
cies but, considering the local malaria epidemiology, it
was almost certainly P.  falciparum. A local physician
treated him with oral artesunate for three days and sulf-
adoxine/pyrimethamine, as a single dose of three tablets,
with good effect. He did not recall the dose of artesunate
but it was probably either 50 mg bid or 100 mg bid on the
first day followed by 50 mg twice a day, consistent with
the artesunate formulations likely to be available locally.
However, 14 days after as the last dose of artesunate, he
presented in Geneva with fever and his blood slide was
positive for P.falciparum with an asexual parasitaemia of
190,000/μL, consistent with a probable recrudescence of
his primary illness rather than a new infection (PCR una-
vailable). He was cured with the six doses regimen of arte-
mether/lumefantrine.
In summary, these three non-immune expatriate workers
suffered of probable falciparum malaria treatment failure
after initial diagnosis and artemisinin-based treatment in
Africa. It must be emphasized that the initial diagnosis
could not be ascertained as malaria blood slides were not
available for quality control. Considering the great varia-
bility in quality of diagnostic procedures in African labo-
ratories, local diagnosis of malaria may not always be
accurate.Malaria Journal 2006, 5:81 http://www.malariajournal.com/content/5/1/81
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All patients reported having completed their treatment
without episode of vomiting. The early timings of their
recurrent malaria are consistent with recrudescence, but in
the absence of PCR genotyping the possibility of early
reinfections cannot be definitively excluded. Similarly, in
the absence of defined plasmatic drug levels, none of
these patients' recurrences meets the WHO definition of
drug resistance [12]. Sub-optimal drug dosing is the likely
explanation for the treatment failures in all three patients.
Patient 1 took artemether for an inadequate duration (five
days only) and suffered recurrent malaria four days after
completing her treatment. Patient 2 failed with the four
dose regimen of artemether/lumefantrine, an expected
finding in non-immunes [9]. Patient 3 had probably
taken insufficient artesunate during the first three days.
His total dose was probably either 400 mg (200 mg day 1,
100 mg days 2 & 3) or 300 (100 mg/d) mg. These doses
translate to a mean of 1.9 and 1.4 mg/kg daily, respec-
tively, and are less than half of the current recommenda-
tion of 4 mg/kg (~300 mg for a 70 kg man) of artesunate
daily when used in combination. However, the failure to
clear parasites following an adult dose of sulfadoxine/
pyrimethamine (S/P) is consistent with S/P resistance.
Several artemisinin-containing therapies and their pack-
aging were reviewed in order to assess the role of inade-
quate manufacturer information and insufficient drug
content as possible causes of malaria treatment failure in
sub-Saharan Africa.
Methods
Packages of artemisinin-containing therapies currently
sold in Africa were obtained from returning patients,
WHO Roll Back Malaria, and the Internet. The list of
twenty-five specialities presented here is not exhaustive
(Table 1), but can reasonably be considered as represent-
ative of the current African market.
Results
The majority (10/17) of manufacturers of artemisinin
monotherapies recommend five days of treatment instead
of the WHO recommended seven days. Only three drug
packages had paediatric dosing and none had specific rec-
ommendations for non-immune patients e.g. that 5 days
of treatment is likely to be inadequate. Some packages
contained less tablets than indicated in the package insert.
The package inserts included in combination treatments
were generally better, with doses both for children (7/8)
and adults and with sufficient tablets to complete a thera-
peutic course. Of note was the use of the lower dose of
mefloquine (15 mg/kg) rather than the higher dose (25
mg/kg) that is used in multidrug resistant areas of SE Asia.
Discussion
Sub-optimal antimalarial therapy results in increased
morbidity and mortality of individuals living in malaria
endemic areas, as well as travellers and expatriate workers
[13,14]. Whilst well-established risk factors include poor
compliance, fake drugs, limited training of drug vendors,
high cost and drug resistance [15-17], little attention has
focused on the number of packaged tablets and the qual-
ity of information in package inserts. Both are crucial ele-
ments in the successful treatment of malaria. Many
patients in endemic countries buy antimalarial drugs
without prior medical consultation from local markets,
small shops, pharmacies and mobile street vendors. Most
would probably assume that one drug package contains a
therapeutic course. Travellers and field workers probably
have the same assumptions as local residents. Clearly,
drugs that are sold already packaged with insufficient tab-
lets to make up a therapeutic course carry a risk of treat-
ment failure, which is increased further, if not all of the
packaged drugs are taken. Drugs at parasiticidal concen-
trations need to act on at least four asexual erythrocytic
cycles to eliminate all asexual malaria parasites; thus, a
minimum of six days of therapeutic drug concentrations
is required [1]. Published data document failure rates of
50% with three days of artesunate in Africans, 50% with
five days of artesunate in Vietnamese patients, and 18%
with the for four doses regimen of artemether/lumefan-
trine in European travellers [5,7,9].
This study shows that a substantial number of artemisi-
nin-based drugs currently sold in Africa do not respect cur-
rent WHO recommendations in term of treatment
duration in case of monotherapy and many lack appropri-
ate information regarding children dosage. Packages con-
taining fewer pills than indicated in the manufacturers
leaflet were also found. Concerning the use of low dose of
mefloquine (15 mg/kg) in combination treatment, this
may not be a problem in the short term in Africa where
mefloquine as monotherapy or combined with artesunate
has shown high efficacy in recent trials. Nevertheless,
great care should be taken in monitoring cure rate, as this
lower dose may potentially favour the development of
mefloquine resistance [18-20].
Conclusion
Travellers, NGO and other workers should be aware not
only of the hazards of contracting malaria, but also how
to obtain optimal treatment. This is especially relevant for
those who may be located in remote rural areas. Drug
manufacturers should also play their part in reducing the
risks of treatment failure. It is suggested that all currently
available artemisinin-based monotherapies should be
packaged for adults and children with a complete thera-
peutic course of seven days of treatment, that package
























































































































Table 1: Examples of artemisinin-based monotherapies and combinations currently sold in Africa for the treatment of uncomplicated falciparum malaria with summarized informations 
provided by the manufacturer on the accompanying package insert.
Trade name Drug substance/s Tablet 
strength (mg)






Artekin – 02 dihydroartemisinin+ piperaquine 40/320 160/1280 7–10 y 80/640 11–15 y 60/480 2 8 Hualijian
Artekin dihydroartemisinin+ piperaquine 40/320 160/1280 7–10 y 80/640 11–15 y 60/480 2 8 Holleykin pharmaceutical
Duo-cotecxin dihydroartemisinin+ piperaquine 40/320 160/1280 7–10 y 80/640 11–15 60/480 2 8 Beijing Holley-Cotec
Coartem artemether+ lumefantrine 20/120 D1 160/960, D2-3 80/480 
or D1-3 160/960
5–15 kg 40/240 16–25 kg 80/480 
26–35 kg 120/720
3 16–24 Novartis
Artequin artesunate + mefloquine 200/250 200/250 NA 3 3 + 3 Mepha
Arsucam (infants and children) artesunate + amodiaquine 50/153 NA 1–7 y 50/153 7–13 y 100/306 3 3 3 + 3 6 + 6 Sanofi-Aventis
Arsucam (adults) artesunate + amodiaquine 50/153 200/612 NA 3 12 + 12 Sanofi-Aventis
Larimal artesunate + amodiaquine 50/153 200/612 4 mg/kg (AS) + 10 mg/kg (AM) 3 12 + 12 Ipca
Monotherapies
Artesunate tablets artesunate 50 D1 200, D2-5 100 NA 5 6 Guilin pharmaceutical
Arinate artesunate 100 D1 200, D2-5 100 D1 3.2 mg/kg, D2-5 1.6 mg/kg 5 6 Dafra
Arsumax artesunate 50 D1 200, D2-5 100 D1 4 mg/kg, D2-5 2 mg/kg 5 12 Sanofi-Aventis
Cotexin artesunate 60 D1 120, D2-5/7 60 NA 5–7 NA Cotec
Artesunate injection artesunate 60 NA NA NA NA Guilin pharmaceutical
Arte-biosorp artesunate 75 300 NA 7 NA Hovid
Artenex artesunate NA D1 4tab, D2-5 2tab D1 3.2 mg/kg, D2-5 2 mg/kg 5 12 Kinapharma
Malarin 200 artesunate 200 D1 400, D2-5 200 D1 4 mg/kg, D2-5 2 mg/kg 
(infants) D1 200, D2-5 100 
(children)
56 t r i - h e a l t h
Plasmotrim 200 artesunate 200 D1 400, D2-5 200 NA 5 6 Mepha
Plasmotrim 50 artesunate 50 NA D1 10 mg/kg, D2-5 5 mg/kg 5 12 Mepha
Gvither forte kit injection artemether 80 D1 240, D2-5 80 D1 4 mg/kg, D2-5 2 mg/kg 5 6 Gvs labs
Gvither forte tablets artemether 80 D1 240, D2-5 80 D1 4 mg/kg, D2-5 2 mg/kg 5 6 Gvs labs
Larither capsule artemether 40 D1 4 mg/kg, D2-5 2 mg/kg NA 7 6 Ipca
Capsulae artemetheri artemether 40 D1 160, D2-5 80 NA 5–7 10 Kunming pharmaceutical
Arte-biosorp artemisinin 75 150 NA 7 30 Hovid
Malaxin dihydroartemisinin 60 D1 120, D2-5/7 60 NA 7 8 Cho dang 
pharmaceutical
Cotecxin dihydroartemisinin 60 D1 120, D2-5/7 60 D1 60, D2-7 30 7 8 Jiaxing nanhu
Abbreviations: NA: information not available. D1,2,3: first, second, third day of treatment. Y: year. Tab: tabletsMalaria Journal 2006, 5:81 http://www.malariajournal.com/content/5/1/81
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of treatment must be taken even if patients feel well. In
view of recent WHO recommendations, manufacturers
should shift their production in favour of combined ther-
apies rather than monotherapy to avoid the development
of resistance for what is often called the 'last effective
weapon against falciparum malaria'. Written information
should avoid proposing different doses by trying to differ-
entiate patients based on their presumed malaria immune
status, as this may be confusing both for patients and pre-
scribers. Similarly, packaging for combinations should be
explicit, easy to use and contain the requisite number of
tablets. Travellers should be aware that artemether/lume-
fantrine is known as Riamet® in temperate countries and
CoArtem® in malaria-endemic countries. Adult Riamet®
contains 24 tablets (six dose regimen) but adult CoArtem®
contains only 16 tablets (4 dose regimen). Setting interna-
tional standards on package inserts might be a useful step
that could be championed by a relevant international
body. The training of local drug sellers and community
health workers in malaria endemic countries is another
strategy that could be adopted.
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